[Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis--secondary publication]

Ugeskr Laeger. 2005 Jun 20;167(25-31):2772-4.
[Article in Danish]

Abstract

Cannabinoids reduce allodynia/hyperalgesia in animal pain models, but few clinical studies evaluated the analgesic action in humans. We aimed to evaluate the effect of delta-9-tetrahydrocannabinol (dronabinol) on central pain in MS patients. Twenty-four MS patients participated in a double-blind placebo-controlled crossover trial. Dronabinol reduced the spontaneous pain intensity significantly compared with placebo (4.0 (2.3-6.0) vs. 5.0 (4.0-6.4), median (25th-75th percentiles), p = 0.02). Though dronabinol's analgesic effect is modest, its use should be evaluated considering the general difficulty in treating central pain.

Publication types

  • Clinical Trial
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Analgesics, Non-Narcotic / administration & dosage*
  • Cross-Over Studies
  • Double-Blind Method
  • Dronabinol / administration & dosage*
  • Dronabinol / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Pain / drug therapy*
  • Pain / etiology
  • Pain / prevention & control
  • Pain Measurement
  • Treatment Outcome

Substances

  • Analgesics, Non-Narcotic
  • Dronabinol